Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0·015% gel: A randomized, controlled 12-month study

British Journal of Dermatology

Volumn 174, Issue 3, 2016, Pages 505-513

  Garbe, Claus ^a   Basset Seguin, N ^b   Poulin, Y ^c,d   Larsson, T ^e   Osterdal M L ^e   Venkata, R ^e   Lear, J T ^f  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITÉ LAVAL   (Canada)

^d Center for Research in Geomatics   (Canada)

^e LEO PHARMA A S   (Denmark)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; FLUOROURACIL; IMIQUIMOD; INGENOL MEBUTATE; 3-INGENYL ANGELATE; DERMATOLOGICAL AGENT; DITERPENE; GEL;

ACTINIC KERATOSIS; ADULT; APPLICATION SITE PRURITUS; ARTICLE; BASAL CELL CARCINOMA; BOWEN DISEASE; CARCINOMA IN SITU; CONTROLLED STUDY; DISEASE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EYELID EDEMA; FEMALE; FOLLOW UP; HEADACHE; HUMAN; KERATOACANTHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIORBITAL EDEMA; PHASE 3 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; ADOLESCENT; AGED; CLINICAL TRIAL; CUTANEOUS DRUG ADMINISTRATION; GEL; KERATOSIS, ACTINIC; MIDDLE AGED; RETREATMENT; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; DERMATOLOGIC AGENTS; DITERPENES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GELS; HUMANS; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; RETREATMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84953775435     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14222     Document Type: Article

References (32)

1. Einspahr JG, Stratton SP, Bowden GT, et al,. Chemoprevention of human skin cancer. Crit Rev Oncol Hematol 2002; 41: 269-85.
2. Vatve M, Ortonne JP, Birch-Machin MA, et al,. Management of field change in actinic keratosis. Br J Dermatol 2007; 157 (Suppl. 2): 21-4.
3. Mittelbronn MA, Mullins DL, Ramos-Caro FA, et al,. Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol 1998; 37: 677-81.
4. Czarnecki D, Meehan CJ, Bruce F, et al,. The majority of cutaneous squamous cell carcinomas arise in actinic keratoses. J Cutan Med Surg 2002; 6: 207-9.
5. Fernandez-Figueras MT, Carrato C, Saenz X, et al,. Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol 2015; 29: 991-7.
6. Berman B, Cockerell CJ,. Pathobiology of actinic keratosis: ultraviolet-dependent keratinocyte proliferation. J Am Acad Dermatol 2013; 68 (Suppl. 1): S10-9.
7. Criscione VD, Weinstock MA, Naylor MF, et al,. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009; 115: 2523-30.
8. Werner RN, Sammain A, Erdmann R, et al,. The natural history of actinic keratosis: a systematic review. Br J Dermatol 2013; 169: 502-18.
9. Frost C, Williams G, Green A,. High incidence and regression rates of solar keratoses in a queensland community. J Invest Dermatol 2000; 115: 273-7.
10. Lebwohl M, Swanson N, Anderson LL, et al,. Ingenol mebutate gel for actinic keratosis. N Engl J Med 2012; 366: 1010-9.
11. Lebwohl M, Shumack S, Gold LS, et al,. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol 2013; 149: 666-70.
12. Rosen R, Marmur E, Anderson L, et al,. A new, objective, quantitative scale for measuring local skin responses following topical actinic keratosis therapy with ingenol mebutate. Dermatol Ther 2014; 4: 207-19.
13. Ceilley RI, Jorizzo JL,. Current issues in the management of actinic keratosis. J Am Acad Dermatol 2013; 68: S28-38.
14. Shergill B, Zokaie S, Carr AJ,. Non-adherence to topical treatments for actinic keratosis. Patient Prefer Adherence 2013; 8: 35-41.
15. Lebwohl M, Malgaard A, Kobayashi K, et al,. Local skin responses associated with ingenol mebutate gel for the treatment of actinic keratosis: two analyses of pooled data. J Am Acad Dermatol 2012; 66 (Suppl. 1): AB153.
16. Berman B, Goldenberg G, Hanke W, et al,. Efficacy and safety of ingenol mebutate 0.015% gel 3 weeks after cryosurgery of actinic keratosis: 11-week results. J Drugs Dermatol 2014; 13: 154-60.
17. Berman B, Goldenberg G, Hanke CW, et al,. Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results. J Drugs Dermatol 2014; 13: 741-7.
18. Nindl I, Gottschling M, Krawtchenko N, et al,. Low prevalence of p53, p16(INK4a) and Ha-ras tumour-specific mutations in low-graded actinic keratosis. Br J Dermatol 2007; 156 (Suppl. 3): 34-9.
19. Hameetman L, Commandeur S, Bavinck JN, et al,. Molecular profiling of cutaneous squamous cell carcinomas and actinic keratoses from organ transplant recipients. BMC Cancer 2013; 13: 58.
20. Padilla RS, Sebastian S, Jiang Z, et al,. Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression. Arch Dermatol 2010; 146: 288-93.
21. Zalaudek I, Giacomel J, Schmid K, et al,. Dermatoscopy of facial actinic keratosis, intraepidermal carcinoma, and invasive squamous cell carcinoma: a progression model. J Am Acad Dermatol 2012; 66: 589-97.
22. Berman B,. New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel. Clin Cosmet Investig Dermatol 2012; 5: 111-22.
23. Rosen RH, Gupta AK, Tyring SK,. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol 2012; 66: 486-93.
24. Cozzi SJ, Ogbourne SM, James C, et al,. Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches. J Invest Dermatol 2012; 132: 1263-71.
25. Cozzi SJ, Le TT, Ogbourne SM, et al,. Effective treatment of squamous cell carcinomas with ingenol mebutate gel in immunologically intact SKH1 mice. Arch Dermatol Res 2013; 305: 79-83.
26. Ulrich M, Lange-Asschenfeldt S, Röwert-Huber J, et al,. Ingenol mebutate gel 500 mcg/g (0.05%) is efficacious in treating subclinical actinic keratoses in a field with cancerisation-assessment by reflectance confocal microscopy. Presented at the 22nd EADV Congress, Istanbul, Turkey, 2-3 October 2013 [Abstr. P534].
27. Pomerantz H, Hogan D, Eilers D, et al,. Long-term efficacy of topical fluorouracil cream, 5%, for treating actinic keratosis: a randomized clinical trial. JAMA Dermatol 2015; 151: 952-60.
28. Samorano LP, Torezan LA, Sanches JA,. Evaluation of the tolerability and safety of a 0.015% ingenol mebutate gel compared to 5% 5-fluorouracil cream for the treatment of facial actinic keratosis: a prospective randomized trial. J Eur Acad Dermatol Venereol 2015; 29: 1822-7.
29. Vegter S, Tolley K,. A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. PLoS One 2014; 9: e96829.
30. Salasche SJ, Levine N, Morrison L,. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial. J Am Acad Dermatol 2002; 47: 571-7.
31. Berman B, Nestor MS, Newburger J, et al,. Treatment of facial actinic keratoses with aminolevulinic acid photodynamic therapy (ALA-PDT) or ingenol mebutate 0.015% gel with and without prior treatment with ALA-PDT. J Drugs Dermatol 2014; 13: 1353-6.
32. 2 on the forearm(s) of patients with actinic keratosis. J Clin Aesthet Dermatol 2014; 7: 19-29.